Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions

GLIA

Volumn 60, Issue 10, 2012, Pages 1468-1480

  Clarner, Tim ^a   Diederichs, Felix ^a   Berger, Katharina ^a   Denecke, Bernd ^b   Gan, Lin ^b   van der Valk, Paul ^c   Beyer, Cordian ^a   Amor, Sandra ^c,d   Kipp, Markus ^c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Demyelination; Gray matter; Inflammation; Myelin

Indexed keywords

CUPRIZONE; MYELIN; MYELIN DEBRIS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN HOMOGENATE; CONTROLLED STUDY; CORPUS CALLOSUM; DEMYELINATION; EXPERIMENTAL DEMYELINATION; GLIOSIS; GRAY MATTER; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEREOTACTIC PROCEDURE; WHITE MATTER LESION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANIMALS; CALCIUM-BINDING PROTEINS; CHELATING AGENTS; CORPUS CALLOSUM; CUPRIZONE; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALITIS; FEMALE; GLIOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MICROGLIA; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN PROTEOLIPID PROTEIN; MYELIN SHEATH; NERVE FIBERS, MYELINATED; NERVE TISSUE PROTEINS; RNA, MESSENGER;

EID: 84865339274     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22367     Document Type: Article

References (45)

1. Acs P, Kipp M, Norkute A, Johann S, Clarner T, Braun A, Berente Z, Komoly S, Beyer C. 2009. 17 beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice. Glia 57: 807-814.
2. Amato MP, Bartolozzi ML, Zipoli V, Portaccio E, Mortilla M, Guidi L, Siracusa G, Sorbi S, Federico A, De Stefano N. 2004. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 63: 89-93.
3. Amato MP, Portaccio E, Goretti B, Zipoli V, Battaglini M, Bartolozzi ML, Stromillo ML, Guidi L, Siracusa G, Sorbi S, Federico A, De Stefano N. 2007. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 64: 1157-1161.
4. Baertling F, Kokozidou M, Pufe T, Clarner T, Windoffer R, Wruck CJ, Brandenburg LO, Beyer C, Kipp M. 2010. ADAM12 is expressed by astrocytes during experimental demyelination. Brain Res 1326: 1-14.
5. Barnett MH, Prineas JW. 2004. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 55: 458-468.
6. Bo L, Geurts JJ, van der Valk P, Polman C, Barkhof F. 2007. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch Neurol 64: 76-80.
7. Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. 2003a. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 9: 323-331.
8. Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. 2003b. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 62: 723-732.
9. Braun A, Dang J, Johann S, Beyer C, Kipp M. 2009. Selective regulation of growth factor expression in cultured cortical astrocytes by neuro-pathological toxins. Neurochem Int 55: 610-618.
10. Brink BP, Veerhuis R, Breij EC, van der Valk P, Dijkstra CD, Bo L. 2005. The pathology of multiple sclerosis is location-dependent: No significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol 64: 147-155.
11. Bruck W. 2005. Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. J Neurol 252 (Suppl 5): v10-v15.
12. De Groot CJ, Bergers E, Kamphorst W, Ravid R, Polman CH, Barkhof F, van der Valk P. 2001. Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: Increased yield of active demyelinating and (p)reactive lesions. Brain 124(Pt 8): 1635-1645.
13. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. 2010. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 162: 1-11.
14. Gehrmann J, Matsumoto Y, Kreutzberg GW. 1995. Microglia: Intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 20: 269-287.
15. Geurts JJ, Barkhof F. 2008. Grey matter pathology in multiple sclerosis. Lancet Neurol 7: 841-851.
16. Groebe A, Clarner T, Baumgartner W, Dang J, Beyer C, Kipp M. 2009. Cuprizone treatment induces distinct demyelination, astrocytosis, and microglia cell invasion or proliferation in the mouse cerebellum. Cerebellum 8: 163-174.
17. Hoffmann K, Lindner M, Groticke I, Stangel M, Loscher W. 2008. Epileptic seizures and hippocampal damage after cuprizone-induced demyelination in C57BL/6 mice. Exp Neurol 210: 308-321.
18. Hudson LC, Bragg DC, Tompkins MB, Meeker RB. 2005. Astrocytes and microglia differentially regulate trafficking of lymphocyte subsets across brain endothelial cells. Brain Res 1058: 148-160.
19. Kacimi R, Giffard RG, Yenari MA. 2011. Endotoxin-activated microglia injure brain derived endothelial cells via NF-kappaB, JAK-STAT and JNK stress kinase pathways. J Inflamm 8: 7.
20. Kipp M, Clarner T, Dang J, Copray S, Beyer C. 2009. The cuprizone animal model: New insights into an old story. Acta Neuropathol 118: 723-736.
21. Kipp M, Gingele S, Pott F, Clarner T, van der Valk P, Denecke B, Gan L, Siffrin V, Zipp F, Dreher W, Baumgartner W, Pfeifenbring S, Godbout R, Amor S, Beyer C. 2011. BLBP-expression in astrocytes during experimental demyelination and in human multiple sclerosis lesions. Brain Behav Immun 25: 1554-1568.
22. Kipp M, Norkute A, Johann S, Lorenz L, Braun A, Hieble A, Gingele S, Pott F, Richter J, Beyer C. 2008. Brain-region-specific astroglial responses in vitro after LPS exposure. J Mol Neurosci 35: 235-243.
23. Koutsoudaki PN, Skripuletz T, Gudi V, Moharregh-Khiabani D, Hildebrandt H, Trebst C, Stangel M. 2009. Demyelination of the hippocampus is prominent in the cuprizone model. Neurosci Lett 451: 83-88.
24. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H. 2005. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128(Pt 11): 2705-2712.
25. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. 2004. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 364: 2106-2112.
26. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Bruck W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM. 2011. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365: 2188-2197.
27. Ludwin SK. 2006. The pathogenesis of multiple sclerosis: Relating human pathology to experimental studies. J Neuropathol Exp Neurol 65: 305-318.
28. Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ. 2007. Lesion genesis in a subset of patients with multiple sclerosis: A role for innate immunity? Brain 130 (Pt 11): 2800-2815.
29. Matsushima GK, Morell P. 2001. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11: 107-116.
30. McFarland HF, Martin R. 2007. Multiple sclerosis: A complicated picture of autoimmunity. Nat Immunol 8: 913-919.
31. Moharregh-Khiabani D, Blank A, Skripuletz T, Miller E, Kotsiari A, Gudi V, Stangel M. 2010. Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse. PLoS One 5: e11769.
32. Norkute A, Hieble A, Braun A, Johann S, Clarner T, Baumgartner W, Beyer C, Kipp M. 2009. Cuprizone treatment induces demyelination and astrocytosis in the mouse hippocampus. J Neurosci Res 87: 1343-1355.
33. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. 2001. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50: 389-400.
34. Pott F, Gingele S, Clarner T, Dang J, Baumgartner W, Beyer C, Kipp M. 2009. Cuprizone effect on myelination, astrogliosis and microglia attraction in the mouse basal ganglia. Brain Res 1305: 137-149.
35. Remington LT, Babcock AA, Zehntner SP, Owens T. 2007. Microglial recruitment, activation, and proliferation in response to primary demyelination. Am J Pathol 170: 1713-1724.
36. Sellner J, Kraus J, Awad A, Milo R, Hemmer B, Stuve O. 2011. The increasing incidence and prevalence of female multiple sclerosis-A critical analysis of potential environmental factors. Autoimmun Rev 10: 495-502.
37. Skripuletz T, Lindner M, Kotsiari A, Garde N, Fokuhl J, Linsmeier F, Trebst C, Stangel M. 2008. Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am J Pathol 172: 1053-1061.
38. Sun X, Wang X, Chen T, Li T, Cao K, Lu A, Chen Y, Sun D, Luo J, Fan J, Young W, Ren Y. 2010. Myelin activates FAK/Akt/NF-kappaB pathways and provokes CR3-dependent inflammatory response in murine system. PLoS One 5: e9380.
39. Takasaki C, Yamasaki M, Uchigashima M, Konno K, Yanagawa Y, Watanabe M. 2010. Cytochemical and cytological properties of perineuronal oligodendrocytes in the mouse cortex. Eur J Neurosci 32: 1326-1336.
40. van der Valk P, Amor S. 2009. Preactive lesions in multiple sclerosis. Curr Opin Neurol 22: 207-213.
41. van der Valk P, De Groot CJ. 2000. Staging of multiple sclerosis (MS) lesions: Pathology of the time frame of MS. Neuropathol Appl Neurobiol 26: 2-10.
42. van Horssen J, Brink BP, de Vries HE, van der Valk P, Bo L. 2007. The blood-brain barrier in cortical multiple sclerosis lesions. J Neuropathol Exp Neurol 66: 321-328.
43. Venturini G. 1973. Enzymic activities and sodium, potassium and copper concentrations in mouse brain and liver after cuprizone treatment in vivo. J Neurochem 21: 1147-1151.
44. Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG. 2006. Microglia potentiate damage to blood-brain barrier constituents: Improvement by minocycline in vivo and in vitro. Stroke 37: 1087-1093.
45. Zou LP, Pelidou SH, Abbas N, Deretzi G, Mix E, Schaltzbeerg M, Winblad B, Zhu J. 1999. Dynamics of production of MIP-1alpha, MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation of immune responses during experimental autoimmune neuritis in Lewis rats. J Neuroimmunol 98: 168-175.